Associate Professor Gavin Marx

Associate Professor
Medicine, Sydney Adventist Hospital Clinical School

Telephone 02 94765844
Fax 02 94821341

Map

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
  • Mahon, K., Qu, W., Devaney, J., Paul, C., Castillo, L., Wykes, R., Chatfield, M., Boyer, M., Stockler, M., Marx, G., Gurney, H., Horvath, L., et al (2014). Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. British Journal of Cancer, 111(9), 1802-1809. [More Information]
  • Smith, M., Saad, F., Oudard, S., Shore, N., Fizazi, K., Sieber, P., Tombal, B., Damiao, R., Marx, G., Miller, K., et al (2013). Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration-Resistant Prostrate Cancer: Exploratory Analysis by Baseline Prostate-Specific Antigen Doubling Time. Journal of Clinical Oncology, 31(30), 3800-3806. [More Information]
  • von Moos, R., Body, J., Egerdie, B., Stopeck, A., Brown, J., Damyanov, D., Fallowfield, L., Marx, G., Cleeland, C., Patrick, D., et al (2013). Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Supportive Care in Cancer, 21(12), 3497-3507. [More Information]
  • Won, A., Gurney, H., Marx, G., de Souza, P., Patel, M. (2013). Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU International, 112(4), E250-E255. [More Information]
  • Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis, N. (2012). The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer, 75(2), 248-254. [More Information]
  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Cummins, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]
  • Kao, S., Hovey, E., Marx, G. (2011). Second-line therapy for castrate-resistant prostate cancer: A literature review. Asia-Pacific Journal of Clinical Oncology, 7, 212-223. [More Information]
  • Hoovey, E., Marx, G., Kneebone, A., Patel, M., Shapiro, J. (2009). An Australian clinical perspective: management of hormone refractory (androgen-independent) prostate cancer. Asia Pacific Journal of Oncology and Hematology, 1, 1.
  • Gananadha, S., Hazebroek, E., Leibman, S., Berry, H., Osgood, L., Shon, I., Pavlakis, N., Marx, G., Smith, G. (2008). The utility of FDG-PET in the preoperative staging of esophageal cancer. Diseases of the Esophagus, 21(5), 389-394. [More Information]
  • Steer, C., Chrystal, K., Cheong, K., Galani, E., Marx, G., Strickland, A., Yip, D., Lofts, F., Gallagher, C., Thomas, H., et al (2006). Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study. Gynecologic Oncology, 103(2), 439-445. [More Information]
  • Marx, G., Taylor, J., Goldstein, D. (2005). Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience. Internal Medicine Journal, 35(1), 34-38. [More Information]
  • Marx, G., Steer, C., Harper, P. (2005). Reply to the letter Limitations of bedside estimates of renal function" by M. J. Dooley and S. G. Poole". Annals of Oncology, 16, 990.
  • Ring, A., Marx, G., Steer, C., Prendiville, J., Ellis, P. (2003). Poor uptake of influenza vaccinations in patients receiving cytotoxic chemotherapy. International Journal of Clinical Practice, 57(6), 542-543. [More Information]
  • Galani, E., Marx, G., Steer, C., Culora, G., Harper, P. (2003). Pseudomyxoma peritonei: the 'controversial' disease. International Journal Of Gynecological Cancer, 13(4), 413-418. [More Information]

2014

  • Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
  • Mahon, K., Qu, W., Devaney, J., Paul, C., Castillo, L., Wykes, R., Chatfield, M., Boyer, M., Stockler, M., Marx, G., Gurney, H., Horvath, L., et al (2014). Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. British Journal of Cancer, 111(9), 1802-1809. [More Information]

2013

  • Smith, M., Saad, F., Oudard, S., Shore, N., Fizazi, K., Sieber, P., Tombal, B., Damiao, R., Marx, G., Miller, K., et al (2013). Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration-Resistant Prostrate Cancer: Exploratory Analysis by Baseline Prostate-Specific Antigen Doubling Time. Journal of Clinical Oncology, 31(30), 3800-3806. [More Information]
  • von Moos, R., Body, J., Egerdie, B., Stopeck, A., Brown, J., Damyanov, D., Fallowfield, L., Marx, G., Cleeland, C., Patrick, D., et al (2013). Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Supportive Care in Cancer, 21(12), 3497-3507. [More Information]
  • Won, A., Gurney, H., Marx, G., de Souza, P., Patel, M. (2013). Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU International, 112(4), E250-E255. [More Information]

2012

  • Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis, N. (2012). The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer, 75(2), 248-254. [More Information]

2011

  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Cummins, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]
  • Kao, S., Hovey, E., Marx, G. (2011). Second-line therapy for castrate-resistant prostate cancer: A literature review. Asia-Pacific Journal of Clinical Oncology, 7, 212-223. [More Information]

2009

  • Hoovey, E., Marx, G., Kneebone, A., Patel, M., Shapiro, J. (2009). An Australian clinical perspective: management of hormone refractory (androgen-independent) prostate cancer. Asia Pacific Journal of Oncology and Hematology, 1, 1.

2008

  • Gananadha, S., Hazebroek, E., Leibman, S., Berry, H., Osgood, L., Shon, I., Pavlakis, N., Marx, G., Smith, G. (2008). The utility of FDG-PET in the preoperative staging of esophageal cancer. Diseases of the Esophagus, 21(5), 389-394. [More Information]

2006

  • Steer, C., Chrystal, K., Cheong, K., Galani, E., Marx, G., Strickland, A., Yip, D., Lofts, F., Gallagher, C., Thomas, H., et al (2006). Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study. Gynecologic Oncology, 103(2), 439-445. [More Information]

2005

  • Marx, G., Taylor, J., Goldstein, D. (2005). Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience. Internal Medicine Journal, 35(1), 34-38. [More Information]
  • Marx, G., Steer, C., Harper, P. (2005). Reply to the letter Limitations of bedside estimates of renal function" by M. J. Dooley and S. G. Poole". Annals of Oncology, 16, 990.

2003

  • Ring, A., Marx, G., Steer, C., Prendiville, J., Ellis, P. (2003). Poor uptake of influenza vaccinations in patients receiving cytotoxic chemotherapy. International Journal of Clinical Practice, 57(6), 542-543. [More Information]
  • Galani, E., Marx, G., Steer, C., Culora, G., Harper, P. (2003). Pseudomyxoma peritonei: the 'controversial' disease. International Journal Of Gynecological Cancer, 13(4), 413-418. [More Information]

To update your profile click here. For support on your academic profile contact .